Perlara announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of nephrologist and kidney disease researcher Dr. Karl Skorecki.

APOL1 kidney disease is a group of nondiabetic chronic progressive kidney diseases which include forms of hypertension with reduced kidney function, Focal Segmental Glomerulosclerosis, lupus nephritis and HIV associated nephropathy. There are two common APOL1 (apolipoprotein) risk variants, G1 and G2, that increase incidence of kidney disease in African Americans and sub-Saharan African populations via an unknown mechanism. Individuals with two risk variants are at a greatly increased risk for developing progressive kidney disease, often with urinary protein leakage. Genetic risk for APOL1 kidney disease affects ~100 million people worldwide, with approximately 50% of African Americans and a similar percentage of the sub-Saharan African population carrying at least one risk allele. With dialysis and kidney transplants being the only treatment, there is an urgent need for a therapeutic approach.

In this PerlQuest, Perlara will adapt the APOL1 G1 and G2 risk allele fly models generated by Dr. Skorecki's research team to its screening platform. Additionally, Perlara will engineer and phenotype APOL1 G1 and G2 risk allele nematode models. Perlara will then screen its drug repurposing library on these models to identify repurposable approved drugs as well as GRAS (generally recognized as safe) compounds that rescue the disease phenotypes in the fly and nematode models.

"APOL1 kidney disease affects millions of people, and there is no available therapeutic approach," said Perlara Director of R&D Nina DiPrimio, Ph.D. "We are excited to embark on this drug discovery effort in collaboration with Dr. Karl Skorecki, a leading expert in APOL1 kidney disease.  The fly G1 and G2 risk allele models developed by his team exhibit screenable phenotypes ready for Perlara's platform. Both the nematode and fly phenotypic drug screens will yield actionable data that will set the foundation for the discovery of repurposable clinical candidates."

"The ability to leverage precision disease risk gene discovery with advanced technologies for therapeutic drug discovery to address an important population health disparity and challenge, is an exciting opportunity for our research team," said Dr. Skorecki.

Dr. Skorecki currently serves as Dean of the Azrieli Faculty of Medicine of Bar-Ilan University, and his research team is based at the Rambam Health Care Campus and Technion – Israel Institute of Technology in Haifa, Israel.

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.